<DOC>
	<DOCNO>NCT02695550</DOCNO>
	<brief_summary>This Phase I study ALK/FAK/Pyk2 inhibitor CT-707 patient ALK-positive non-small cell lung cancer . The purpose study determine MTD/RP2D CT-707 evaluate whether CT-707 safe beneficial effect ALK-positive advanced non-small cell lung cancer .</brief_summary>
	<brief_title>Study Safety , Efficacy Pharmacokinetics CT-707 Patients With ALK-positive Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients must diagnose ALKpositive advance NSCLC . The tumor must ALKpositive determined ALK rearrangement ≥15 % cell ( measure FISH use Vysis breakapart ALK probe ) use Ventana ALK IHC test . The analysis may perform locally . Eastern cooperative oncology group ( ECOG ) performance status ≤ 2 . Measurable disease per RECIST v1.1 Availability tumor sample : Patients symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid local CNSdirected therapy control CNS disease Impaired cardiac function clinically significant cardiac disease Patients abnormal laboratory value screen day 1 predose Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption CT707 Patient history pancreatitis history increase amylase lipase due pancreatic disease . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>